TY - JOUR
T1 - Oral toxicity of indium in rats
T2 - Single and 28-day repeated administration studies
AU - Asakura, Keiko
AU - Satoh, Hiroshi
AU - Chiba, Momoko
AU - Okamoto, Masahide
AU - Serizawa, Koji
AU - Nakano, Makiko
AU - Omae, Kazuyuki
PY - 2008
Y1 - 2008
N2 - Indium is widely used in the electronics industry to make semiconductors, liquid-crystal panels, and plasma display panels, and its production is increasing. However, it is necessary to handle it more cautiously than before, because the pulmonary toxicity of inhaled indium has been identified. The present study aimed to characterize the potential toxic effects of indium through oral administration and observation for fourteen days following a single dose of 0 or 2,000 mg/kg (acute oral toxicity study), and repeated oral administration for 28 days at dose levels of 0, 40, 200, or 1,000 mg/kg daily (28-day repeated oral dose toxicity study) to male and female Crj:CD (SD) IGS rats (SPF). No deaths and no abnormalities in clinical signs, body weights, and necropsy findings were observed for any of the animals in the acute oral toxicity study. Furthermore, no changes related to indium were also observed in the dose groups up to 1,000 mg/kg of the 28-day repeated oral dose toxicity study. From the results described above, the lethal dose 50% (LD 50) of indium is greater than 2,000 mg/kg under these study conditions, and the no-observed-adverse-effect-level (NOAEL) is considered to be 1,000 mg/kg for males and females under these conditions.
AB - Indium is widely used in the electronics industry to make semiconductors, liquid-crystal panels, and plasma display panels, and its production is increasing. However, it is necessary to handle it more cautiously than before, because the pulmonary toxicity of inhaled indium has been identified. The present study aimed to characterize the potential toxic effects of indium through oral administration and observation for fourteen days following a single dose of 0 or 2,000 mg/kg (acute oral toxicity study), and repeated oral administration for 28 days at dose levels of 0, 40, 200, or 1,000 mg/kg daily (28-day repeated oral dose toxicity study) to male and female Crj:CD (SD) IGS rats (SPF). No deaths and no abnormalities in clinical signs, body weights, and necropsy findings were observed for any of the animals in the acute oral toxicity study. Furthermore, no changes related to indium were also observed in the dose groups up to 1,000 mg/kg of the 28-day repeated oral dose toxicity study. From the results described above, the lethal dose 50% (LD 50) of indium is greater than 2,000 mg/kg under these study conditions, and the no-observed-adverse-effect-level (NOAEL) is considered to be 1,000 mg/kg for males and females under these conditions.
KW - Indium
KW - Oral toxicity
KW - Rat
UR - http://www.scopus.com/inward/record.url?scp=59749096708&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=59749096708&partnerID=8YFLogxK
U2 - 10.1539/joh.L8070
DO - 10.1539/joh.L8070
M3 - Article
C2 - 18931462
AN - SCOPUS:59749096708
SN - 1341-9145
VL - 50
SP - 471
EP - 478
JO - Journal of Occupational Health
JF - Journal of Occupational Health
IS - 6
ER -